TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer

Table 2 Clinicopathological Characteristics and TP53 Mutational Analysis

Characteristics	Number of total patients	(%)	P^c	Number of TP53 Mutations	(%)	P^d
Parity			0.019*			0.042*
0-1	77	47.8		59	48.0
2-3	66	41.0		57	46.3
>3	15	9.3		7	5.7
Peritoneal metastasis			0.004*			0.027*
yes	89	55.3		79	64.2
no FIGO stage	71	44.1	0.025*	44	35.8	0.024*
I	55	34.2		33	26.8
II	18	11.2		17	13.8
III	80	49.7		66	53.7
IV	7	4.3		7	5.7
Histotype			0.954			0.114
serous	91	56.5		70	56.9
mucinous	22	13.7		16	13.0
endometrioid	23	14.3		13	10.6
clear cell	16	9.9		15	12.2
undifferentiated	9	5.6		9	7.3
WHO grade			0.415			0.068
G1	33	20.5		22	17.9
G2	57	35.4		39	31.7
G3	69	42.9		62	50.4
Tumor grade^a			0.003*			0.002*
low-grade	57	35.4		33	26.8
high-grade	101	62.7		90	73.2
CA125 (Uml^–1) ^b			0.001*			0.508
≤ 206.52	86	53.4		51	41.5
> 206.52	46	28.6		39	31.7
Residual tumor (cm)			<0.0001*			0.102
≤ 0.5	119	73.9		86	69.9
> 0.5	40	24.8		37	30.1
Platinum resistance			<0.0001*			0.161
yes	36	22.4		33	26.8
no	123	76.4		90	73.2

a: In accordance with morphological and molecular genetic analysis, EOC was divided into two categories [28]
b: Based on patient survival, the cutoff value of CA125 calculated with a receiver operating characteristic (ROC) was 206.52 (Uml–1)
c: p value for clinicopathological characteristics
d: p value for TP53 mutation
*p < 0.05

ISSN: 1746-1596